Citadel Advisors’s Cytosorbents Corp CTSO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $6.12K | Sell |
10,799
-138,480
| -93% | -$94.5K | ﹤0.01% | 12803 |
|
|
2025
Q4 | $95.4K | Buy |
149,279
+83,589
| +127% | +$64.3K | ﹤0.01% | 11681 |
|
|
2025
Q3 | $61.4K | Buy |
+65,690
| New | +$64.7K | ﹤0.01% | 12092 |
|
|
2025
Q2 | – | Sell |
-8,183
| Closed | -$8.22K | – | 12909 |
|
|
2025
Q1 | $8.18K | Buy |
+8,183
| New | +$8.62K | ﹤0.01% | 13653 |
|
|
2024
Q4 | – | Sell |
-29,087
| Closed | -$28.5K | – | 14638 |
|
|
2024
Q3 | $43.6K | Buy |
+29,087
| New | +$31.9K | ﹤0.01% | 12059 |
|
|
2023
Q4 | – | Sell |
-30,688
| Closed | -$57.7K | – | 14383 |
|
|
2023
Q3 | $57.7K | Sell |
30,688
-7,113
| -19% | -$20.4K | ﹤0.01% | 11582 |
|
|
2023
Q2 | $136K | Buy |
37,801
+24,609
| +187% | +$77.8K | ﹤0.01% | 10480 |
|
|
2023
Q1 | $44.5K | Buy |
+13,192
| New | +$39.6K | ﹤0.01% | 12312 |
|
|
2022
Q3 | – | Sell |
-126,898
| Closed | -$278K | – | 12757 |
|
|
2022
Q2 | $278K | Buy |
126,898
+104,296
| +461% | +$239K | ﹤0.01% | 9963 |
|
|
2022
Q1 | $73K | Buy |
22,602
+1,780
| +9% | +$6.38K | ﹤0.01% | 12544 |
|
|
2021
Q4 | $87K | Sell |
20,822
-40,735
| -66% | -$229K | ﹤0.01% | 12844 |
|
|
2021
Q3 | $500K | Buy |
61,557
+30,142
| +96% | +$245K | ﹤0.01% | 9863 |
|
|
2021
Q2 | $237K | Buy |
31,415
+7,777
| +33% | +$65.5K | ﹤0.01% | 11798 |
|
|
2021
Q1 | $205K | Sell |
23,638
-45,568
| -66% | -$434K | ﹤0.01% | 11643 |
|
|
2020
Q4 | $552K | Sell |
69,206
-60,597
| -47% | -$507K | ﹤0.01% | 7951 |
|
|
2020
Q3 | $1.03M | Buy |
129,803
+34,164
| +36% | +$308K | ﹤0.01% | 5967 |
|
|
2020
Q2 | $947K | Buy |
95,639
+85,192
| +815% | +$782K | ﹤0.01% | 5933 |
|
|
2020
Q1 | $81K | Sell |
10,447
-17,204
| -62% | -$86.8K | ﹤0.01% | 8771 |
|
|
2019
Q4 | $106K | Buy |
+27,651
| New | +$121K | ﹤0.01% | 8523 |
|
|
2019
Q2 | – | Sell |
-16,037
| Closed | -$121K | – | 9253 |
|
|
2019
Q1 | $121K | Buy |
+16,037
| New | +$125K | ﹤0.01% | 8482 |
|
|
2018
Q2 | – | Sell |
-11,291
| Closed | -$107K | – | 8874 |
|
|
2018
Q1 | $80K | Buy |
+11,291
| New | +$85.3K | ﹤0.01% | 7787 |
|
|
2016
Q4 | – | Sell |
-16,527
| Closed | -$106K | – | 7318 |
|
|
2016
Q3 | $106K | Buy |
+16,527
| New | +$85.9K | ﹤0.01% | 6631 |
|
|
2015
Q4 | – | Sell |
-8,451
| Closed | -$53K | – | 8775 |
|
|
2015
Q3 | $53K | Sell |
8,451
-1,843
| -18% | -$12.3K | ﹤0.01% | 7538 |
|
|
2015
Q2 | $63K | Buy |
+10,294
| New | +$70K | ﹤0.01% | 7495 |
|
Other funds holding CTSO
AC
VCM
SC
CM
SIG
VFT
Citadel Advisors's CTSO Position: Q1 2026 in Review
Citadel Advisors reduced its Cytosorbents Corp (CTSO) stake by 93% in Q1 2026, selling an estimated $94.5K and leaving 10,799 shares worth $6.12K. The position accounts for ﹤0.01% of the portfolio, ranked #12803.
Citadel Advisors first reported a position in CTSO in Q2 2015 and has held it in 24 quarters since. The position peaked at $1.03M in Q3 2020. 50 funds tracked by Wall St. Rank hold CTSO as of Q1 2026.
- Citadel Advisors held 10,799 shares of Cytosorbents Corp worth $6.12K as of Q1 2026.
- Citadel Advisors sold 138,480 Cytosorbents Corp shares in Q1 2026, an estimated $94.5K.
- Cytosorbents Corp made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12803 holding.
- Citadel Advisors first reported a position in Cytosorbents Corp in Q2 2015 and has held it in 24 quarters since.
- Citadel Advisors's Cytosorbents Corp position peaked at $1.03M in Q3 2020.
- 50 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.